Envestnet Portfolio Solutions Inc. Has $234,000 Stock Position in Takeda Pharmaceutical Co. $TAK

Envestnet Portfolio Solutions Inc. raised its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 29.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,112 shares of the company’s stock after purchasing an additional 3,410 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Takeda Pharmaceutical were worth $234,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of TAK. Farther Finance Advisors LLC lifted its holdings in Takeda Pharmaceutical by 21.7% in the second quarter. Farther Finance Advisors LLC now owns 5,623 shares of the company’s stock valued at $87,000 after buying an additional 1,003 shares during the period. GAMMA Investing LLC raised its position in shares of Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after acquiring an additional 1,296 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at $125,000. Hexagon Capital Partners LLC boosted its position in shares of Takeda Pharmaceutical by 52.9% in the 1st quarter. Hexagon Capital Partners LLC now owns 8,698 shares of the company’s stock worth $129,000 after purchasing an additional 3,008 shares during the last quarter. Finally, Entropy Technologies LP bought a new stake in Takeda Pharmaceutical in the first quarter valued at about $156,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Down 0.2%

NYSE:TAK opened at $14.03 on Friday. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.69. The stock has a 50-day moving average price of $14.75 and a two-hundred day moving average price of $14.73. The stock has a market cap of $44.63 billion, a price-to-earnings ratio of 46.75 and a beta of 0.21. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, equities analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on TAK. Weiss Ratings restated a “hold (c+)” rating on shares of Takeda Pharmaceutical in a report on Tuesday, October 14th. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.